Watson Rebecca’s Pacira BioSciences PCRX Stock Holding History

Watson Rebecca’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,000	Closed	-$52K	–	281
2020 Q2	$52K	Buy	+1,000	New	+$41.8K	0.03%	157

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Watson Rebecca's PCRX Position: Q3 2020 in Review

Watson Rebecca sold out of Pacira BioSciences (PCRX) in Q3 2020, closing a stake of 1,000 shares — an estimated $52K sold.

Watson Rebecca first reported a position in PCRX in Q2 2020 and held it in 1 quarter. The position peaked at $52K in Q2 2020. 257 funds tracked by Wall St. Rank hold PCRX as of Q3 2020.

Watson Rebecca reported no remaining Pacira BioSciences position as of Q3 2020 after selling out during the quarter.
Watson Rebecca sold 1,000 Pacira BioSciences shares in Q3 2020, an estimated $52K.
Watson Rebecca first reported a position in Pacira BioSciences in Q2 2020 and held it in 1 quarter.
Watson Rebecca's Pacira BioSciences position peaked at $52K in Q2 2020.
257 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2020.

Based on Watson Rebecca's 13F filing for Q3 2020, filed 22 Oct 2020.